Cardio Diagnostics Receives Preliminary Medicare Pricing From CMS For AI-Powered Cardiovascular Tests, Marking Key Milestone Toward Securing Medicare Reimbursement For PrecisionCHD And Epi+Gen CHD
Portfolio Pulse from Benzinga Newsdesk
Cardio Diagnostics has received preliminary Medicare pricing from CMS for its AI-powered cardiovascular tests, PrecisionCHD and Epi+Gen CHD. This is a significant step towards securing Medicare reimbursement.
October 01, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardio Diagnostics has received preliminary Medicare pricing for its AI-powered cardiovascular tests, PrecisionCHD and Epi+Gen CHD, from CMS. This marks a significant step towards securing Medicare reimbursement, potentially increasing the adoption and revenue of these tests.
The preliminary Medicare pricing is a crucial step for Cardio Diagnostics as it moves towards securing reimbursement. This development could lead to increased adoption of their tests, positively impacting revenue and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100